EyEnovia, Inc. Files 8-K for Material Definitive Agreement

TL;DR

EYEN files 8-K for material agreement - big news incoming.

AI Summary

On April 8, 2024, EyEnovia, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal executive offices in New York, NY, filed this 8-K report to disclose this significant event. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates a significant development for EyEnovia, Inc., potentially impacting its business operations, financial standing, and future strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

• EYENOVIA, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• New York, NY (location) — Principal Executive Offices
• April 8, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — on which registered) Common stock, $0.0001 par value EYEN The Nasdaq Stock Mar
• $0.6204 — res"). The offering price per Share was $0.6204. The Purchase Agreement contains custo
• $2.0 million — fering are expected to be approximately $2.0 million. The Company intends to use the net pro

Filing Documents

• tm2411385d1_8k.htm (8-K) — 30KB
• tm2411385d1_ex10-1.htm (EX-10.1) — 186KB
• 0001104659-24-045015.txt ( ) — 429KB
• eyen-20240408.xsd (EX-101.SCH) — 3KB
• eyen-20240408_lab.xml (EX-101.LAB) — 33KB
• eyen-20240408_pre.xml (EX-101.PRE) — 22KB
• tm2411385d1_8k_htm.xml (XML) — 4KB

01. Entry Into a Material Definitive

Item 1.01. Entry Into a Material Definitive Agreement. Registered Direct Offering On April 8, 2024, Eyenovia, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with a single fundamentals-based healthcare investor (the "Purchaser"), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the "Offering"), 3,223,726 shares of common stock, par value $0.0001 per share (the "Shares"). The offering price per Share was $0.6204. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing and indemnification obligations of the Company and the Purchaser. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement and as of a specific date, were solely for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties. The aggregate gross proceeds to the Company from the Offering are expected to be approximately $2.0 million. The Company intends to use the net proceeds from the Offering to fund commercialization activities for its products, Mydcombi and clobetasol propionate, to complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes. The Offering is being made pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333-261638), as previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"), and a related prospectus. The Offering is expected to close on or about April 11, 2024, subject to the satisfaction of customary closing conditions. The foregoing summary of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Purchase Agreement, which is filed as Exhibit 10.1 to th

Forward-Looking Statements

Forward-Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this Current Report on Form 8-K are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements relating to the Company's future activities or other future events or conditions, including statements regarding the completion of the Offering, the intended use of net proceeds from the Offering, and potential regulatory approvals and accessible markets for the Company's product candidates. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which the Company files with the SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, the Company does not undertake any obligation to update any forward-looking statements.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Securities Purchase Agreement, dated April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: April 9, 2024 /s/ John Gandolfo John Gandolfo Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR